A Single Amino Acid Substitution Makes WNK4 Susceptible to SB 203580 and SB 202190

Mark Glover¹, Connor Sweeney¹, Bill Davis² and Kevin M. O'Shaughnessy*¹

¹Clinical Pharmacology Unit, Department of Medicine, University of Cambridge, Cambridge, UK;
²GlaxoSmithKline Clinical Unit, Addenbrooke’s Hospital, Cambridge, UK

Abstract: Regulation of the SLC12 family of membrane transporters including NCCT involves a scaffold of interacting proteins including the STE 20 kinase SPAK and the WNK kinases, WNK 1 and WNK 4, which are mutated in the hypertensive syndrome of pseudohypoaldosteronism type 2 (PHAII). WNK4 regulates NCCT by affecting forward trafficking to the surface membrane. Studies in Xenopus using kinase dead WNK4 site mutants have produced inconsistent results with regard to the necessity of kinase function for NCCT regulation. Dynamic inhibition of WNK4 by small molecules may bring clarity to this issue however WNK4 is naturally resistant to commercial MAP kinase inhibitors owing to steric constraints prohibiting entry of small molecules to the active site. Using an approach similar to that used in p38 and ERK, we show that a single substitution in WNK4 (T261G) dramatically enhances its susceptibility to the inhibitors SB 202190 and SB 203580.

Keywords: WNK kinases, protein kinase inhibitors, active site, transporters, sequence mutagenesis.

INTRODUCTION

Protein kinases form a fundamental network of intracellular signalling molecules necessary for most human signal transduction pathways. Abnormal kinase function has been associated with disease processes as diverse as cancer [1], diabetes [2], rheumatoid arthritis [3] and hypertension [4]. Recent therapeutic advances using small cell permeable kinase inhibitors have yielded dramatic results; for example the BCR-ABL inhibitor Imatinib, effective in Chronic Myeloid leukaemia [5] and the mTOR inhibitor Rapamycin for preventing transplant rejection [6] and have also revolutionised our understanding of signal transduction pathways themselves [7].

Kinases may contribute to hypertension either by augmenting arteriolar vasoconstriction by Rho kinase [8] or by increasing sodium retention in the distal renal tubule through regulation of ENaC by SGK1 [9] and NCCT by WNK kinases [4]. WNK kinases (With No Lysine Kinases) are a family of four kinases of which the genes for WNK1 and WNK4 are mutated in Gordon syndrome or Pseudohypoaldosteronism type II (PHA II), a rare monogenic form of hypertension. A model in which WNK1 inhibits WNK4 that in turn inhibits NCCT forward trafficking to the apical membrane is well established [4], although the effect of WNK4 kinase function in regulating NCCT expressed in Xenopus using kinase dead site mutants has yielded inconsistent results [10-12]. A major limitation in the exploration of WNK kinase function in Xenopus as well as in tissues and whole animals has been the absence of specific inhibitors.

The pyridinyl imidazoles SB 203580 and SB 202190 were developed at SmithKline Beecham as inhibitors of IL-1 and TNF production in activated monocytes [13]. Radioligand binding assay subsequently identified the kinase targets now known as the stress activated MAPK kinases, SAPK2a/p38α and SAPK2b/p38β. These SB compounds were used to elucidate some of the physiological effects of this pathway [14], as well as identifying downstream targets of the kinases [14-16]. X-ray crystallography of SB 203580 bound to p38 kinase revealed the drug binding to the ATP binding pocket and allowed adjacent residues in the pocket to be identified [17]. Threonine106 is located close to the 4-fluorophenyl ring of the inhibitor Fig. (1) and mutation to the more bulky M106 retards kinase inhibition [14, 17, 18]. In fact, a series of T106 p38 mutants showed a hierarchy of kinase inhibition with smaller residues such as glycine or alanine allowing maximum drug binding. Using this approach a previously insensitive kinase, ERK 2, was made drug-sensitive by mutation of the homologous residue Q105 to the smaller T105 [19]. Four other closely located residues were also found to modulate ERK2 sensitivity to SB 203580 in a complementary manner.

We hypothesised that in WNK4, mutation of the homologous amino acid T261 to glycine might facilitate binding of small molecule kinase inhibitors such as the SB compounds to the ATP pocket and so confer drug sensitivity permitting dynamic investigation of WNK4 kinase function on the regulation of NCCT.

MATERIALS AND METHODOLOGY

Cloning and cRNA Synthesis

Wild type NCCT in ECFP-TNT with cyan fluorescent protein at its N terminal and wild type WNK4 in pcDNA3 were as previously described [11]. The WNK4 cDNA was mutated to T261G using site directed mutagenesis.
(Stratagene, La Jolla, CA). All sequences were verified using an ABI 377 and Big Dye fluorescent chemistry (Applied Biosystems, Foster City, CA). Copy RNA was transcribed in vitro from linearized plasmids using the T7 mMESSAGE mMACHINE™ kit (Ambion, Austin, TX) and quantified using ultraviolet absorption spectroscopy (Nanodrop, Wilmington, DE).

**Expression in Xenopus Oocytes**

*Xenopus laevis* oocytes were harvested and defolliculated as detailed previously [20]. Briefly, 10 ng of NCCT cRNA was injected in a total volume of 50nl per oocyte, and for coinjections involving WNK4 an additional 10ng cRNA was added to the injectate. RNAase and DNAase free water-injected oocytes were used as controls throughout. Oocytes were then incubated in ND96 containing 2 mM sodium pyruvate, 0.1mg/ml gentamicin and kinase or inhibitors at 18°C for 5 days.

For 22Na⁺ flux studies, oocytes were placed for 24 hours in Cl⁻ free ND96 solution containing 96mM sodium isethionate, 2mM potassium gluconate, 1.8 mM calcium gluconate, 1mM magnesium gluconate, 5mM HEPES, 2.5mM sodium pyruvate and 5mg/dl gentamicin. Thirty minutes before the addition of uptake medium, oocytes were added to Cl⁻ free ND96 with inhibitors (1mM ouabain, 100µM amiloride and 100µM bumetanide) according to the protocol of Gamba [21]. Oocytes were then transferred to isotonic uptake medium (58mM NaCl, 38mM M-methyl-D-glucamine, 2mM KCl, 1.8mM CaCl₂ and 5mM HEPES with inhibitors pH 7.4) containing 22Na⁺ at a final concentration of 2.5µCi/ml and incubated in a gently shaking incubator at 37°C for 1 hour. Oocytes were then washed five times with 3ml ice cold aliquots of isotonic medium and the oocytes counted individually in a gamma counter (Perkin-Elmer Cobra 5003). Thiazide sensitivity was confirmed using 100µM hydrochlorothiazide (data not shown).

Membrane surface expression measurements were performed 5 days after injection by laser-scanning confocal microscopy with a Leica DMRXA confocal microscope. Data was captured using an equatorial section through each oocyte under a x10 objective lens with brightness, contrast and pin-hole settings kept constant for all oocytes in each injection series. The fluorescent signal in the membrane was quantified using Leica confocal software (version 2.61 of LCS Lite®) with sampling made at sixteen equispaced points on the circumference and averaged to give mean total fluorescence intensity in arbitrary fluorescence units (AFUs).

**Data Analysis**

For all oocyte experiments ten to fifteen oocytes were injected for each cRNA used. Differences between groups were compared by 1-way ANOVA with post hoc testing. Figures show representative experiments that were replicated using at least four different batches of oocytes from different donor animals. The SPSS statistical package (software version 12) was used throughout with significance defined as P < 0.05. The IC50 values for the SB compounds were derived from the fitting of the dose-response curves to a simple logistic function using GraphPad version 4.

**RESULTS**

**T261G Mutant WNK4 Behaves as Wild Type WNK4**

22Na⁺ flux measurable in NCCT injected oocytes was completely inhibited by hydrochlorothiazide (100 µM) as shown in Fig. (2A). Wild type WNK4 coinjection with NCCT decreased 22Na⁺ uptake by 62% (3.0 +/- 0.4 nmol/oocyte/h, P<10⁻⁴) in keeping with previous reports. T261G WNK4 produced a similar effect reducing 22Na⁺ uptake through NCCT by 71% (2.3 +/- 0.4 nmol/ oocyte/h, P<10⁻⁴), which was not significantly different from wild type WNK4 (3.0 +/- 0.4 nmol/oocyte/h, P>0.05).

Confocal microscopy of ECFP-NCCT injected oocytes showed that WNK4 effects on NCCT flux activity were accompanied by parallel changes in surface membrane expression of the transporter Fig. (2B). Wild type WNK4 decreased membrane expression of ECFP-NCCT by 52% (14.1 +/- 1.1 vs. 29.4 +/- 2.6 AFUs, P<10⁻⁴). Similarly T261G WNK4 reduced NCCT surface membrane abundance by 41% (17.2 +/- 1.8 vs. 29.4 +/- 2.6 AFUs, P<10⁻⁴). Again the effects of the two forms of WNK4 kinases were not significantly different from each other (14.1 +/- 1.1 vs. 17.2 +/- 1.8 AFU’s, P>0.05).

**Site Mutation of WNK4 Confers Kinase Inhibitor Sensitivity**

*Xenopus* oocytes were injected with cDNA for ECFP-NCCT with either wild type or the mutant WNK4 T261G. They were then incubated with low (0.5 µM) or high (5µM) concentrations of the SB compounds to see if these kinase inhibitors were able to block the catalytic activity of WNK4 and restore 22Na⁺ uptake. Fig. (3A) shows that 22Na⁺ uptake by wild type WNK4 injected oocytes was unaffected by incubation with either concentration of the SB inhibitors indicating that the IC50 for both SB compounds must be >5 µM against wild type WNK4. Conversely 22Na⁺ flux through
NCCT coinjected with mutant WNK4 T261G was increased when incubated with either inhibitor; the flux actually returning to the level seen in oocytes injected with NCCT alone. The changes in $^{22}\text{Na}^+$ flux, were accompanied by parallel changes in the membrane fluorescence and hence membrane expression of NCCT Fig. (3B).

Concentration Response Curves for SB 202190 and SB 203580

These results in Fig. (3) suggested that the IC50 for both SB compounds was at ~100-fold lower for the T261G mutant versus wild type. To confirm this, concentration-response curves were generated for the SB compounds in oocytes expressing WNK4 T216G. The fitted IC50 values were 109 nM for SB 203580 and 147 nM for SB 202190 Fig. (4).

DISCUSSION AND CONCLUSION

Experiments to study the effects of WNK4 in whole animals and tissues have been hampered by the lack of an inhibitor. Although it is well established that wild type WNK4 inhibits NCCT forward trafficking to the surface membrane [4], it was unclear whether intact kinase function was necessary for this to occur. Studies using kinase dead WNK4 site mutants expressed in Xenopus have yielded inconsistent results [10-12].
may be attractive therapeutically. Salt availability of small molecule inhibitors of wild type WNK4 capable of inhibiting wild type WNK kinases at the site of WNK kinases may enable the design of compounds preventing small molecules from gaining access to the active site thereby affecting NCCT trafficking.

Increasing the effect of WNK4 T261G on NCCT in the oocyte system, enhancement of its sensitivity to SB 202190 and SB203580. The fitted EC50 values (concentration of inhibitor producing 50% reversal) were respectively 147 and 109 nM.

Within the kinome, the WNKs show closest homology to the MAPK subgroup of MAPK kinases. Inhibitors of the MAPK kinase family are well described, although the sensitivity of individual kinases is dependent on steric factors around the ATP binding pocket. In keeping with reports using p38 and ERK2 kinases [14-16, 19], we found that mutation of the single threonine residue at position 261 of WNK4 (homologous amino acid 106 in p38) to a residue with a much smaller side chain resulted in dramatic enhancement of its sensitivity to SB 202190 and SB203580. The IC50 for both agents shifted from >500 nM to ~100 nM, so that both inhibitors were able to completely reverse the effect of WNK4 T261G on NCCT in the oocyte system. These results confirm that WNK4 requires a catalytically intact kinase function to affect NCCT trafficking [10, 11].

It is hoped that further study of the steric constraints preventing small molecules from gaining access to the active site of WNK kinases may enable the design of compounds capable of inhibiting wild type WNK kinases. The availability of small molecule inhibitors of wild type WNK4 may be attractive therapeutically. Salt-retention through increased expression of NCCT could be useful, for example, in hypotensive states such as autonomic failure. It is not clear that a similar strategy could be used for WNK1. Heterozygous mouse knock-outs for WNK1 do have a lowered blood pressure [22], but there are contradictory reports of the necessity for intact WNK1 kinase function to influence NCCT via WNK4 [11, 12]. WNK1 is also found predominantly in the short form which lacks the kinase domain [23], although in states of low potassium diet [24] or Gordon syndrome, the full length transcript may be physiologically more significant [25, 26].

In summary, we have shown that T261G mutation of WNK4 renders it susceptible to inhibition by SB202190 and SB203580 and confirming that the ability of WNK4 to regulate NCCT is indeed dependent on kinase activity. This may be useful in elucidating the role of WNK4 kinase activity in regulating renal electrolyte transport experimentally.

GRANTS

MG was supported by a British Heart Foundation (UK) Clinical Studentship FS/06/034 and a Raymond and Beverley Sackler Studentship.

REFERENCES

[1] Bleeker, F.; Felicioni, L.; Butitta, F.; Lamba, S.; Cardone, L.; Rodolfo, M.; Scarpa, A.; Leenstra, S.; Frattini, M.; Barbareschi, M.; Grammastro, M.; Sciarrotta, M.; Zanon, C.; Marchetti, A.; Bardelli, A. AKT1 E57K in human solid tumors. Oncogene, 2008, 27, 5648-5650.

[2] Asano, T.; Fujishiro, M.; Gabreels, F.; Kushiyama, A.; Nakatsu, Y.; Yonda, M.; Kamata, H.; Sakoda, H. Role of phosphatidylinositol 3-kinase activation on insulin action and its alteration in diabetic conditions. Biol. Pharm. Bull., 2007, 30, 1610-1616.

[3] Okuma-Yoshioka, C.; Seto, H.; Kadono, Y.; Atsuhiko, H.; Oshima, Y.; Kurowsawa, H.; Nakamura, K.; Tanaka, S. Tumor necrosis factor-a inhibits chondrogenic differentiation of synovial fibroblasts through p38 mitogen activating protein kinase pathways. Mod. Rheum., 2008, 18, 366-378.

[4] Cope, G.; Golbang, AP.; O'Shaughnessy, K.M. WNK kinases and the control of blood pressure. Pharmacol. Ther., 2006, 106, 221-231.

[5] O'Brien, S.G.; Guilhot, F.; Larson, R.A. For the IRIS Investigators: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med., 2003, 348, 994-1004.

[6] Kahan, B. For the Rapamune U.S.Study group: Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. Lancet, 2000, 356, 194-202.

[7] Cuenda, A.; Alessi, D.R. Use of Kinase Inhibitors to Dissect Signalling Pathways. Method Mol. Biol., 2001, 99, 161-175.

[8] Tawara, S.; Shimokawa, H. Progress of the study of rho-kinase and future perspective of the inhibitor. Yakugaku Zasshi, 2007, 127, 501-514.

[9] Xu, B.; Stippec, S.; Chu, P.; Lazrak, A.; Li, X.; English, J.; Ortega, B.; Huang, C.; Cobb, M. WNK1 activates SGK1 to regulate the epithelial sodium channel. Proc. Natl. Acad. Sci. USA, 2005, 102, 10315-10320.

[10] Wilson, F.H.; Kahle, K.T.; Sabath, E.; Laiiotti, M.D.; Rapson, A.K.; Hoover, R.S.; Hebert, S.C.; Gamba, G.; Lifton, R.P. Molecular pathogenesis of inherited hypertension with hyperkalemia: the Na Cl cotransporter is inhibited by wild-type but not mutant WNK4. Proc. Natl. Acad. Sci. USA, 2003, 100, 680-684.

[11] Golbang, A.P.; Cope, G.; Hamad, A.; Murthy, M.; Liu, C.-H.; Cuthbert, A.W.; O'Shaughnessy K.M. Regulation of the expression of the Na/Ci cotransporter by WNK4 and WNK1: evidence that accelerated dynamin-dependent endocytosis is not involved. Am. J. Physiol. Renal. Physiol., 2006, 291, F1369-F1376.
WNK4 inhibitors

[12] Yang, C.L.; Zhu, X.; Wang, Z.; Subramanya, A.R.; Ellison, D.H. Mechanisms of WNK1 and WNK4 interaction in the regulation of thiazide-sensitive NaCl cotransport. J. Clin. Invest., 2005, 115, 1379-1387.

[13] Lee, J.C.; Young, P.R. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature, 1994, 372, 739-746.

[14] Cohen, P. The search for physiological substrates of MAP and SAP kinases in mammalian cells. Trends Cell Biol., 1997, 7, 353-361.

[15] Deak, M.; Clifton, A.D.; Lusoq, J.M.; Alessi, D.R. Mitogen- and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38, and may itself mediate activation of CREB. EMBO J., 1998, 17, 4426-4441.

[16] New, L.; Jiang, Y.; Zhao, M.; Liu, K.; Zhu, W.; Flood, L.J.; Kato, Y.; Parry, G.C.; Han, J.H. PRAK, a novel protein kinase regulated by the p38 MAP kinase. EMBO J., 1998, 17, 3384.

[17] Tong, L.; Pav, S.; White, D.M.; Rogers, S.; Crane, K.M.; Cywin, C.L.; Brown, M.L.; Pargellis, C.A. A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket. Nat. Struct. Biol., 1997, 4, 311-316.

[18] Eyres, P.A.; Craxton, M.; Morrice, N.; Cohen, P.; Goedert, M. Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino acid substitution. Chem. Biol., 1998, 5, 321-328.

[19] Fox, E.; Coll, J.T.; Xie, X.; Ford, P.J.; Germann, U.A.; Porter, M.D.; Pazhanisamy, S.; Flenning, M.A.; Galullo, V.; Su, M.S.; Wilson, K.P. A single amino acid substitution makes ERK2 susceptible to pyridyl imidazole inhibitors of p38 MAP kinase. Protein Sci., 1998, 7, 2249-2255.

[20] Golbang, A.P.; Murthy, M.; Hamad, A.; Liu, C-H.; Cope, G.; Van't Hoff, W.; Cutibert, A.W.; O'Shaughnessy K.M. A new kindred with pseudohypoaldosteronism type ii and a novel mutation (S64D=H) in the acidic motif of the WNK4 gene. Hypertension, 2005, 46, 295-300.

[21] Gamba, G.; Miyanoshiba, A.; Lombardi, M.; Lytton, J.; Lee, W.S.; Hediger, M.A.; Hebert, S.C. Molecular cloning, primary structure and characterization of two members of the mammalian electroneutral sodium-potassium-chloride cotransporter family expressed in kidney. J. Biol. Chem., 1994, 269, 17713-17722.

[22] Zabrowicz, B.P.; Abuin, A.; Ramirez-Solis, R.; Richter, L.J.; Piggott, J.; Beltrandelrio, H.; Buxton, E.C.; Edwards, J.; Finch, R.A.; Friddle, C.J.; Gupta, A.; Hansen, G.; Hu, Y.; Huang, W.; Jaing, C.; Key, B.W.; Kipp, P.; Sands, T. WNK1 kinase deficiency lowers blood pressure in mice: A gene-trap screen to identify potential targets for therapeutic intervention. Proc. Natl. Acad. Sci. USA, 2003, 100, 14109-14114.

[23] O'Reilly, M.; Marshall, E.; Speirs, H.J.; Brown, R.W. WNK1, a gene within a novel blood pressure control pathway, tissue-specifically generates radically different isoforms with and without a kinase domain. J. Am. Soc. Nephrol., 2003, 14, 2447-2456.

[24] O'Reil, M.; Marshall, E.; MacGillivray, T.; Mittal, M.; Xue, W.; Kenyon, C.J.; Brown, R.W. Dietary electrolyte-driven responses in the renal WNK kinase pathway in vivo. J. Am. Soc. Nephrol., 2006, 17, 2402-2413.

[25] Wilson, F.H.; Disse-Nicodeme, S.; Chat, K.A.; Ishikawa, K.; Nelsen-Williams, C.; Desitter, J.; Gual, M.; Milford, D.V.; Lipkin, G.W.; Achard, J.M.; Feeley, M.P.; Dussol, B.; Berland, Y.; Unwin, R.J.; Mayan, H.; Simon, D.B.; Farfel, Z.; Jeunemaitre, X.; Lifton, R.P. Human Hypertension caused by mutations in WNK Kinases. Science, 2001, 293, 1107-1112.

[26] Disse-Nicodeme, S.; Desitter, J.; Fiquet-Kempf, B.; Hout, A.; Stern, N.; Delagouesse, M; Potier, J.; Ader, J.; Jeunemaitre, X. Genetic heterogeneity of familial hyperkalaemic hypertension. J. Hypertens., 2001, 19, 1957-1964.